News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
FOSUN PHARMA Once Surges 10%+; Subsidiary's Luvometinib Tablets Receives Drug Registration Approval
FOSUN PHARMA (02196.HK) opened up 2.27% today (30th) and once surged by 10.3% to a peak of HKD16.5. It last traded at HKD16.38, up 9.49%, on a volume of 30.4045 million shares, inv...
Reset
Send
The window will close in 5 seconds
FOSUN PHARMA Once Surges 10%+; Subsidiary's Luvometinib Tablets Receives Drug Registration Approval
Close
Recommend
4
Positive
6
Negative
1
 
SHORT SELL
 
STOCK INFO

FOSUN PHARMA (02196.HK)  -0.560 (-3.196%)    Short selling $24.57M; Ratio 8.175%   opened up 2.27% today (30th) and once surged by 10.3% to a peak of HKD16.5. It last traded at HKD16.38, up 9.49%, on a volume of 30.4045 million shares, involving HKD488 million.

Shanghai Fosun Pharmaceutical Industrial, a subsidiary of Fosun Pharmaceutical, has received approval from China's National Medical Products Administration (NMPA) for the market registration application of its Luvometinib tablets.

Related NewsHSBC Research Expects CN Pharma Firms to Benefit from Biz Development, Prefers HENGRUI PHARMA/ HANSOH PHARMA
It is reported that this is the sixth domestically developed Category 1 innovative drug approved for market in Shanghai this year, and also another rare disease medication to receive approval recently.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-13 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.